Outer membrane vesicle-based pertussis vaccine - Intravacc
Alternative Names: acellular pertussis vaccine; aPV; Avacc 3; OMV-based pertussis vaccine - Intravacc; OMV-based whooping cough vaccine - Intravacc; omvPVLatest Information Update: 28 Oct 2024
At a glance
- Originator Intravacc
- Class Bacterial vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Pertussis
Most Recent Events
- 28 Oct 2024 No recent reports of development identified for phase-I development in Pertussis(Prevention) in Netherlands (Intranasal)
- 28 Jul 2024 No recent reports of development identified for preclinical development in Pertussis(Prevention) in Netherlands (SC)
- 02 May 2022 Outer membrane vesicle-based pertussis vaccine licensed to Zhifei Lvzhu Biopharmaceutical in for China, Africa, South America and select Asian countries